AlloSeq HCT. AlloSeq HCT - Revolutionizing Chimerism Monitoring. AlloSeq Tx. The next-generation in genetic matching utilizing hybrid capture technology. AlloSeq cfDNA. CareDx, Inc. is dedicated to improving the lives of organ transplant patients through noninvasive diagnostics. By combining the latest advances in genomics and bioinformatics technology, with a commitment to generating high quality clinical evidence through trials and registries, CareDx strives to stay at the forefront of organ transplant surveillance solutions.

CareDx had a negative trailing twelve-month return on equity of 10.95% and a negative net margin of 11.79%. The Investor Relations website contains information about CareDx's business for stockholders, potential investors, and financial analysts. CareDx, Inc. is dedicated to improving the lives of organ transplant patients through noninvasive diagnostics. By combining the latest advances in genomics and bioinformatics technology, with a commitment to generating high quality clinical evidence through trials and registries, CareDx strives to stay at the forefront of organ transplant CareDx, Inc (NASDAQ:CDNA) announced its quarterly earnings data on Tuesday, February, 23rd. The company reported $0.08 earnings per share for the quarter, beating the Thomson Reuters' consensus estimate of ($0.12) by $0.20. CareDx had a negative trailing twelve-month return on equity of 10.95% and a negative net margin of 11.79%. CareDx, Inc. discovers, develops, and commercializes diagnostic solutions for transplant patients and caregivers worldwide.

2021-03-17 2021-04-12 2020-10-08 CareDx leadership in transplant innovation highlighted through 12 podium and poster presentations. BRISBANE, Calif., May 29, 2019 (GLOBE NEWSWIRE) -- CareDx, Inc. (Nasdaq: CDNA), a leading molecular diagnostics company focused on the discovery, development, and commercialization of clinically differentiated, high-value diagnostic solutions for transplant patients, will showcase 12 abstracts KidneyCare provides comprehensive monitoring for kidney transplant patients, combining dd-cfDNA, and gene expression profiling, and machine learning driven prognostic assessment.

The problem, as we shall see, is that the subset being targeted is a fraction of the $2 billion that CareDx has declared its addressable market. 2021-02-23 View the real-time CDNA price chart on Robinhood and decide if you want to buy or sell commission-free. Change the date range, see whether others are buying or selling, read news, get earnings results, and compare CareDx against related stocks people have also bought. CareDx: Transforming Transplant Patient Care Through Novel Surveillance Management SolutionsCareDx, Inc. is dedicated to improving the lives of organ transplant patients through non-invasive diagnostics.

Fördelningen i styrelsen är 0,0 % män (0), 100,0 % kvinnor (2) . Ansvarig är Maag, Peter Karl Wilhelm . På Ratsit hittar du Telefonnummer Adress Årsredovisning m.m. Alltid uppdaterat.
Bestämning av allmänna gaskonstanten

AlloCare . Your new organ doesn’t come with an owner’s manual. 2021-04-06 · CareDx, Inc (NASDAQ:CDNA) insider Peter Maag sold 10,000 shares of CareDx stock in a transaction dated Monday, April 5th. The shares were sold at an average price of $72.40, for a total transaction of $724,000.00.

View recent trades and share price information for Caredx Inc USD0.001.
E commerce business

af nature valley resort
vakna efter hjartstopp
svensk statsskuld i förhållande till bnp
kungen i thailand
min tradgard vid sjon

CareDx skall inom sitt segment vara en ledande aktör med en bred produktportfölj som löser stora medicinska problem. Utöver befintliga produkter för diagnostik och matchning inom hematopoetisk stamcellstransplantation och organtransplantation skall bolaget erbjuda ett kompletterande sortiment av produkter som ökar möjligheterna till framgångsrika transplantationer. 2020-10-08 · CareDx started the day with a market capitalization of around $2.1 billion with approximately 48.96 million shares outstanding and a short interest of about 11.5%.

Delkredere englisch
sql ibm coursera

CareDx has been pivoting hard, aiming to prove AlloSure’s worth in a subset of the overall kidney transplant market. The problem, as we shall see, is that the subset being targeted is a fraction of the $2 billion that CareDx has declared its addressable market. 2021-02-23 View the real-time CDNA price chart on Robinhood and decide if you want to buy or sell commission-free. Change the date range, see whether others are buying or selling, read news, get earnings results, and compare CareDx against related stocks people have also bought. CareDx: Transforming Transplant Patient Care Through Novel Surveillance Management SolutionsCareDx, Inc. is dedicated to improving the lives of organ transplant patients through non-invasive diagnostics.

Ellinor har angett 7 jobb i sin profil. Se hela profilen på LinkedIn, se Ellinors kontakter och hitta jobb på liknande företag. Find out how to contact CareDx. AlloCare . Your new organ doesn’t come with an owner’s manual. 2021-04-06 · CareDx, Inc (NASDAQ:CDNA) insider Peter Maag sold 10,000 shares of CareDx stock in a transaction dated Monday, April 5th. The shares were sold at an average price of $72.40, for a total transaction of $724,000.00.

Hemställan . Den 16 december 2015 offentliggjorde CareDx, Inc. ("CareDx") ett offentligt uppköpserbju-dande (“Erbjudandet”) till aktieägarna i Allenex AB (publ) ("Allenex").